Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals

Lin, CP; Liang, PC; Huang, CI; Yeh, ML; Hsu, PY; Hsu, CT; Wei, YJ; Liu, TW; Hsieh, MY; Hou, NJ; Jang, TY; Lin, YH; Wang, CW; Lin, ZY; Chen, SC; Huang, CF; Huang, JF; Dai, CY; Chuang, WL; Yu, ML

Huang, CF (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan.; Huang, CF (corresponding author), Kaohsiung Med Univ, Coll Med, Sch Med, Fac Internal Med, Kaohsiung, Taiwan.; Huang, CF (corresponding author), Kaohsiung Med Univ, Coll Med, Sch Med, Hepatitis Res Ctr, Kaohsiung, Taiwan.; Huang, CF (corresponding author), Kaohsiung Med Univ, Ctr Canc Res & Liquid Biopsy, Kaohsiung, Taiwan.

PLOS ONE, 2021; 16 (2):

Abstract

Background/Aims Undetectable HCV RNA 12 weeks after the end of treatment (SVR12) has been the valid efficacy endpoint in the era of direct-acting anti......

Full Text Link